Introduction
Bone marrow hypoplasia and pancytopenia are among the most problematic sequelae of chemotherapy for the treatment of cancer. They lead to immunodeficiency, bleeding and hypoxia, significantly contributing to the morbidity of cancer patients. Postchemotherapy recovery of the hematopoietic system involves the engagement of hematopoietic stem cells (HSC) in proliferation and differentiation, which is regulated by multiple signals provided by the hematopoietic microenvironment in response to physiological and pathophysiological demands (1) . Cell surface receptors, soluble growth factors and extracellular matrix (ECM) molecules are produced by the cells that compose the hematopoietic microenvironment and contribute to its highly complex structure. The discovery of hematopoietic growth factors led to the development of cytokine-based therapies. Although some factors, such as G-CSF, shorten the period of neutropenia in cancer patients undergoing chemotherapy (2-4), there are side effects that limit their usefulness (5, 6), which prompts the search for novel therapeutic strategies.
There is growing evidence that the hematopoietic microenvironment is an important therapeutic target (7) because the structure and function of the stem cell niche is affected by a variety of pathological conditions or therapeutic interventions. In particular, the composition of the ECM, an important component of the hematopoietic microenvironment (8-11) is affected by irradiation, chemotherapy, hormonal therapy and other agents (12) (13) (14) . One of the important components of the bone marrow ECM is hyaluronic acid (HA), also called hyaluronan, which participates in local ECM assembly by interacting with a variety of other extracellular molecules (15). HA, a member of the Previous studies demonstrated that HA infusion shortened the period of cytopenia in mice treated with 5-fluorouracil (5FU) (28). This correlated with increased numbers of HSCs and committed progenitors in bone marrow of HA-treated mice, suggesting that HA can be used to facilitate hematopoietic recovery in cancer patients post-chemotherapy.
One concern for the use of compounds that stimulate cell proliferation -directly or indirectly -in cancer patients is the risk that the compound or a drug candidate will activate the same proliferative molecular pathways in the residual cancer cells that might Once tumors were established (size of 5×5 mm on day 6), mice were treated with chemotherapy. Control untreated mice were sacrificed when the tumor reached 10 mm 2 size. Tumor weights were established at necropsy.
Chemotherapy Protocol
Mice were injected subcutaneously with irinotecan and 5-fluorouracil (5FU). The mice were treated with chemotherapy starting from day 7 after tumor implantation by injecting 50 mg/kg/week of irinotecan (days 7, 14 and 21) and 50 mg/kg/week 5FU (days 8, 15 and 22) in 24 hour intervals.
HA treatment
Following three rounds of chemotherapy, mice were injected intravenously with 3 mg/kg HA (isolated from human umbilical cord, Sigma, 100 μl) or with vehicle (PBS, control, 100 μl,) on days 28, 31, 34, 37 and 40. HA preparations used in this study were tested for the size distribution using an agarose gel assay, which demonstrated that the size of HA 
Colony forming unit (CFU) assay
Mice were euthanized with an overdose of CO 2 . Femurs were dissected, cleaned of muscle tissue, and the epiphyses were cut off at each end of the femur. The contents of each femur were flushed out of the bone with PBS supplemented with 5% FCS using a needle (25G) attached to a 1-ml syringe. To ensure the preparation of a single cell suspension, the cell suspension was aspirated several times through a larger needle (21G).
The cells were kept on ice until use. Peripheral blood cells were collected by aspiration from the heart using a 21G needle attached to a 1 ml syringe with 100 μl heparin. The cultures were incubated in a humidified incubator with 5% CO 2 in air at 37°C for 7- Expression of endogenous HA in tumors was detected by biotin-conjugated HA-binding protein (bHABP) followed by incubation with FITC-conjugated avidin (Seikagaku, Japan).
FACS analysis
Cell surface expression of CD44 was detected using antibodies HERMES-3 (for CD44s) and VFF-8 (for CD44v5), VFF-18 (for CD44v6), VFF-9 (for CD44v7) and VFF-14 (for 
Results

The tumor model
Since the overall goal of this study was to determine whether exogenous HA facilitates re-growth of tumors after chemotherapy, we selected a tumor model that met the following criteria: 1) ability to grow in mice; 2) sensitivity to chemotherapy; 3) ability of the tumor cells to bind HA; and 4) expression of the HA receptor CD44. The human colon carcinoma cell line HCT-8 forms tumors in immune deficient mice and is sensitive to chemotherapy (37). HCT-8 cells express CD44s and the splice variants CD44v5, CD44v7, CD44v10, but not CD44v6 (Figure 2A) . HCT-8 cells also express low levels of endogenous HA, which was detected by using biotin-conjugated HA-binding protein (bHABP) ( Figure 2B ). In addition, HCT-8 cells are capable to bind exogenous HA as determined by using FITC-conjugated HA ( Figure 2C ).
Next, we tested whether HCT-8 cells are sensitive to 5FU. In vitro treatment of HCT-8 cells with 5 μg/ml 5FU resulted in a changed cell cycle. As expected, the percent of cells in S phase was decreased from 36.1±1.0 to 13.2±3.5. This correlated with the 5-fold decrease in the number of cells recovered from the culture dish. In addition, the percentage of apoptotic cells was increased from 9.5±0.6 to 21.9±1.8. 
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Copyright © 2010 American Association for Cancer Research after termination of the chemotherapy treatment followed by HA infusion, the number of bone marrow cells was two-fold higher in HA-treated mice as compared to control mice injected with PBS ( Figure 3A ) Similarly, the number of hematopoietic progenitors in bone marrow recovered faster in mice treated with chemotherapy followed by HA infusion as compared to controls ( Figure 3B) . Although peripheral blood counts recovered faster in HCT-8 tumor-bearing SCID mice, as compared to previously described models (28), there was a trend to faster recovery of peripheral blood cells in HA-treated mice ( Table 1) .
HA inhibits tumor re-growth after chemotherapy
In order to assure that tumor cells treated with chemotherapy could still respond to HA, ( Figure 4B ). There was a slightly lower body weight in the HA-treated mice, but it was not statistically significant (p=0.055) ( Figure 4C) .
Mechanisms mediating the effect of HA on tumor cells
Tumor growth may be influenced directly by effects on tumor cell proliferation and apoptosis or indirectly by effects on angiogenesis.
First we tested the hypothesis that HA can directly interfere with tumor growth.
Using cell cycle analysis we found that HA did not change the percentage of HCT-8 cells that were in S and G2 phase in an in vitro assay, whether the cells were untreated or following 5FU exposure ( Table 2) 
Discussion
Our earlier studies suggest that HA can be used to facilitate the recovery of hematopoiesis after chemotherapy (28). One concern of using HA in cancer patients is its 
